Norwegian Multiple Sclerosis Registry & Biobank (Norway) **
Kjell-Morten Myhr
Email: kjell-morten.myhr@helse-bergen.no
Phone: +47 55975045
Stig Wergeland, Ph.D.
Head of the Norwegian MS-registry and biobank
Phone: (+47) 55 97 60 30
Email: stig.wergeland@helse-bergen.no
1. König M, Lorentzen ÅR, Torgauten HM, Tran TT, Schikora-Rustad S, Vaage EB, Mygland Å, Wergeland S, Aarseth J, Aaberge IAS, Torkildsen Ø, Holmøy T, Berge T, Myhr KM, Harbo HF, Andersen JT, Munthe LA, Søraas A, Celius EG, Vaage JT, Lund-Johansen F, Nygaard GO. Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. J Neurol Neurosurg Psychiatry. 2023 Jan;94(1):19-22.
2. Høglund RAA, Meyer HE, Stigum H, Torkildsen Ø, Grytten N, Holmøy T, Nakken O. Association of Body Mass Index in Adolescence and Young Adulthood and Long-term Risk of Multiple Sclerosis: A Population-Based Study. Neurology. 2021 Dec 7;97(23):e2253-e2261.
3. Grytten N, Myhr KM, Celius EG, Benjaminsen E, Kampman MT, Midgard R, Vatne A, Aarseth JH, Riise T, Torkildsen Ø. Incidence of cancer in multiple sclerosis before and after the treatment era- a registry- based cohort study. Mult Scler Relat Disord. 2021 Oct;55:103209.
4. Ahmad I, Wergeland S, Oveland E, Bø L. A higher proportion of ermin-immunopositive oligodendrocytes in areas of remyelination. PLoS One. 2021 Aug 26;16(8):e0256155.
5. Norborg H, Riise T, Myhr KM, Grytten N, Wergeland S. Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis. Mult Scler J Exp Transl Clin. 2021 Jun 14;7(2):20552173211022027.
6. Karine Eid, Øivind Fredvik Torkildsen, Jan Aarseth, Heidi Øyen Flemmen, Trygve Holmøy, Åslaug Rudjord Lorentzen, Kjell-Morten Myhr, Trond Riise, Cecilia Simonsen, Cecilie Fredvik Torkildsen, Stig Wergeland, Johannes Sverre Willumsen, Nina Øksendal, Nils Erik Gilhus, Marte-Helene Bjørk. Perinatal Depression and Anxiety in Women With Multiple Sclerosis
A Population-Based Cohort Study. Neurology Jun 2021, 96 (23) e2789-e2800;
7. Torgauten HM, Myhr KM, Wergeland S, Bø L, Aarseth JH, Torkildsen Ø. Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis - A cohort study. Mult Scler J Exp Transl Clin. 2021 Jan 31;7(1):2055217320973049.
8. Grytten N, Myhr KM, Celius EG, Benjaminsen E, Kampman M, Midgard R, Vatne A, Aarseth JH, Riise T, Torkildsen Ø. Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study. Mult Scler. 2020 Oct;26(12):1569-1580.
9. Willumsen JS, Aarseth JH, Myhr KM, Midgard R. High incidence and prevalence of MS in Møre and Romsdal County, Norway, 1950-2018. Neurol Neuroimmunol Neuroinflamm. 2020 Mar 26;7(3):e713.
10. Cortese M, Riise T, Bjørnevik K, Myhr KM; Multiple Sclerosis Conscript Service Database Study Group. Body size and physical exercise, and the risk of multiple sclerosis. Mult Scler. 2018 Mar;24(3):270-278.